Mayne Pharma US manufactures, markets and/or distributes more than 66 drugs in the United States. To learn more about generic pharmaceuticals and how they both increase access and decrease health-care costs, visit 1538 Main North Road, Salisbury South, SA 5106, Australia Mayne Pharma offers a comprehensive portfolio of branded and generic drugs, with distribution throughout the United States.. Non-US country and region specific information is not available on this page. Generic Products. MAYNE PHARMA ADDS TWO SPECIALTY PRODUCTS TO ITS AUSTRALIAN PORTFOLIO 15 Sep 2017, Adelaide Australia: Mayne Pharma Group Limited (ASX: MYX) received Therapeutic Goods Administration (TGA) approval for Monurol ® (fosfomycin) granules used for the treatment of urinary tract infections (UTIs) . US Customer Service. US Products. Mayne Pharma releases Doryx ® MPC (doxycycline hyclate delayed-release tablets) 120 mg NEW Doryx MPC is a tetracycline-class antimicrobial indicated as adjunctive therapy for severe acne. To view our existing products, please visit our product catalog. In 2015 the combined market for these products was approximately $8.3 million according to IMS Health. Mayne Pharma is committed to providing high levels of service and our experienced local Customer Service Team is here to help.For US product enquiries and purchase orders call us at +1 800 344 8661 or To report SUSPECTED ADVERSE REACTIONS, contact Mayne Pharma at 1-844-825-8500 or FDA at 1 800-FDA-1088 or 1538 Main North Road, Salisbury South, SA 5106, Australia Mayne Pharma is committed to providing high levels of service and our experienced local Customer Service Team is here to help. For more than 30 years now, Mayne Pharma has developed high-quality generic products to offer patients improved access and affordable options to medications that enhance their lives. For more than 30 years now, Mayne Pharma has developed high-quality generic products to offer patients improved access and affordable options to medications that enhance their lives. Medications listed here may also be marketed under different names in different countries. Mayne Pharma is continuously adding to its portfolio of generic pharmaceuticals — adding more of the cost-effective, life-enhancing medications patients need. Our robust portfolio of generic products highlights Mayne Pharma’s known expertise for advanced, complex and niche pharmaceuticals. Shares rallied on the news, with the stock up 9.8 per cent at the open on Monday, to 45¢ just after 10am. Specialty Brands. On 21 August 2020, Mayne Pharma releases its full-year results for FY20 (ended 30 June 2020). New Products Our commitment to you just got stronger. If you’d like to speak with a Mayne Pharma representative, please call 1-800-344-8661 or email Generic prescription drugs saved American consumers $293 billion in 2018 and now represent 90 percent of all prescriptions filled in the United States annually, according to the Mayne Pharma is proud to apply its successful track record of pharmaceutical innovation to developing new generic drugs that offer patients greater access to more affordable medications. Mayne has two facilities established in Greenville, the US and Salisbury, Australia with expertise in the development of complex oral and topical dose forms comprising poorly soluble compounds, modified-release products, and potent compounds. H2-Pharma, LLC announced today that it has acquired the exclusive rights to distribute fifteen (15) products from Mayne Pharma, Inc. 1538 Main North Road, Salisbury South, SA 5106, Australia T +61 8 8209 2666 F +61 8 8281 6998 We add new products to our portfolio through acquisition and partnerships as well as internal drug development driven by our own pharmaceutical scientists. Mayne Pharma wants to expand its reach in the US contraception market.